Sentinel Lymph Node Biopsy Guideline Update: Main Takeaway

Sentinel Lymph Node Biopsy Guideline Update: Multidisciplinary Discussion

Sentinel Lymph Node Biopsy Guideline Update: Axillary Ultrasound

Sentinel Lymph Node Biopsy Guideline Update: Systemic Therapy

Sentinel Lymph Node Biopsy Guideline Update: Radiation

Sentinel Lymph Node Biopsy Guideline Update: Treatment Intensity Should Match Recurrence Risk

Sentinel Lymph Node Biopsy Guideline Update: Current Recommendations

Sentinel Lymph Node Biopsy Guideline Update: SOUND & INSEMA Trial

Sentinel Lymph Node Biopsy Guideline Update: Risks

Sentinel Lymph Node Biopsy Guideline Update: Overview

Extended Endocrine Therapy Study: Key Takeaways

Extended Endocrine Therapy Study: Proportion of Patients Receiving Endocrine Therapy

Extended Endocrine Therapy Study: Adverse Events

Extended Endocrine Therapy Study: Subgroup Results

Extended Endocrine Therapy Study: Distant Recurrence

Extended Endocrine Therapy Study: Primary Endpoint

Extended Endocrine Therapy Study: Patient Characteristics

Extended Endocrine Therapy Study: Study Design

Extended Endocrine Therapy Study: Objective

Extended Endocrine Therapy Study: Overview

Early-Stage ER+ BRCA-BC: Evidence Gap

Early-Stage ER+ BRCA-BC: Biomarkers

Early-Stage ER+ BRCA-BC: PARP vs. CDK4/6

Early-Stage ER+ BRCA-BC: Who Qualifies for Olaparib in Practice

Early-Stage ER+ BRCA-BC: Oncotype DX

Early-Stage ER+ BRCA-BC: Prognosis

Early-Stage ER+ BRCA-BC: Two Options, No Roadmap

Early-Stage ER+ BRCA-BC: CDK4/6 Inhibitors

Early-Stage ER+ BRCA-BC: OlympiA Trial

Early-Stage ER+ BRCA-BC: Treatment Landscape

RJBC 1501 Trial: Clinical Implications

RJBC 1501 Trial: Safety Profile

RJBC 1501 Trial: Subgroup Analysis

RJBC 1501 Trial: Overall Survival

MELODY Trial: Clinical Implications

RJBC 1501 Trial: Distant Disease-Free Survival

MELODY Trial: Anxiety Outcome Results

RJBC 1501 Trial: Disease-Free Survival

RJBC 1501 Trial: Patient Characteristics

MELODY Trial: Study Design & Endpoints

RJBC 1501 Trial: Study Design & Endpoints

RJBC 1501 Trial: Clinical Background

MELODY Trial: Study Overview

RJBC 1501 Trial: Study Overview

Liberalized vs Neutropenic Diet Phase III Trial: Key Takeaways

Liberalized vs Neutropenic Diet Phase III Trial: Nutritional Intake

Liberalized vs Neutropenic Diet Phase III Trial: Bloodstream Infections

Liberalized vs Neutropenic Diet Phase III Trial: Key Result

Liberalized vs Neutropenic Diet Phase III Trial: Population Characteristics

Liberalized vs Neutropenic Diet Phase III Trial: Trial Design

Liberalized vs Neutropenic Diet Phase III Trial: Overview

SunRISe-4: Safety Profile & Next Steps

SunRISe-4: Biomarker Data & Strategies

SunRISe-4: Recurrence-Free Survival

SunRISe-4: Pathologic Response Rates

SunRISe-4: Trial Overview

IDeate-Lung01: Safety Profile

IDeate-Lung01: Brain Metastases & CNS Control

IDeate-Lung01: Activity Across Treatment Lines

IDeate-Lung01: Rapid Responses & Durability